healthprotocol.wiki

dowling-liblik_2025_rct_inavolisib-lengthens-progression-free-survival-time-in-her2-negative-advanced-breast-cancer

6 findings

Protocol
medication-cancer-inavolisib-plus-palbociclib-and-fulvestrant
Outcome
oncology-duration-of-response-median-months
n
161
effect
70
attribution
85
Protocol
medication-cancer-inavolisib-plus-palbociclib-and-fulvestrant
Outcome
oncology-objective-response-rate-percent
n
161
effect
75
attribution
85
Protocol
medication-cancer-inavolisib-plus-palbociclib-and-fulvestrant
Outcome
safety-overall-adverse-events-occurrence
n
161
effect
0
attribution
85
Protocol
medication-cancer-inavolisib-plus-palbociclib-and-fulvestrant
Outcome
safety-serious-adverse-events-rate-percent
n
161
effect
-50
attribution
85
Protocol
medication-cancer-inavolisib-plus-palbociclib-and-fulvestrant
Outcome
safety-treatment-discontinuation-due-to-adverse-events-rate-percent
n
161
effect
-55
attribution
85
Protocol
medication-cancer-inavolisib-plus-palbociclib-and-fulvestrant
Outcome
survival-progression-free-median-months
n
161
effect
80
attribution
85